Company: MBIO
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001410578-25-000028
Chunk: 79

Company: MUSTANG BIO, INC.
Filing Date: 2025-01-15
Form: S-1
Chunk 79
---
 pronouncements interpreting laws and regulations; |

| ● | changes in government programs; |

| ● | announcements of new products, services or technologies, commercial relationships, acquisitions or other events by us or our competitors; |

| ● | market conditions in the pharmaceutical and biotechnology sectors; |

| ● | fluctuations in stock market prices and trading volumes of similar companies; |

| ● | changes in accounting principles; |

| ● | litigation or public concern about the safety of our product candidates or similar product candidates; |

| ● | sales of large blocks of our common stock, including sales by our executive officers, directors and significant shareholders; and |

| ● | our ability to obtain additional financing to advance our development operations; |

51

These broad market and industry factors may decrease the market price of our common stock, regardless of our actual operating performance. The stock market in general has from time to time experienced extreme price and volume fluctuations. In addition, in the past, following periods of volatility in the overall market and decreases in the market price of a company’s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management’s attention and resources.

We may become involved in securities class action litigation that could divert management’s attention and harm our business.

The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of biotechnology and pharmaceutical companies. These broad market fluctuations may cause the market price of our stock to decline. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. We may become involved in this type of litigation in the future. Litigation often is expensive and diverts management’s attention and resources, which could adversely affect our business.

If we are unable to maintain compliance with all applicable continued listing requirements and standards of Nasdaq, our common stock may be delisted from Nasdaq.

Our common stock is listed on the Nasdaq Capital Market under the symbol “MBIO.” The Nasdaq Capital Market requires that listed companies satisfy continued listing standards to maintain their listing. On March 13, 2024, we received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that